AI Summary

Researchers have demonstrated that a single intravenous infusion of a harmless engineered virus can reprogram a patient’s own immune cells, producing effects similar to CAR T‑cell therapy. The approach, tested in an early‑stage trial, aims to redirect immune activity toward combating autoimmune diseases rather than cancer. By delivering the virus intravenously, the method simplifies the complex manufacturing steps traditionally required for CAR T‑cell treatments. The study suggests a potentially faster, less invasive strategy for immune‑reprogramming, though further clinical evaluation is needed.

AI summaries can be wrong sometimes—always verify important details using the source article.